MBX - Quick Take - Key Takeaways from Obesity Day; focus on obesity and canvu

Research evidence excerpt

MBX - Quick Take - Key Takeaways from Obesity Day; focus on obesity and canvu

% body weight reduction after 3w showed expected PD effects but without projectile

vomiting as typically seen, other side effects consistent with incretins/DACRAs (dehydration, lethargy) recovered within the first week.

Of note, NHPs are expected to clear this prodrug 3x as fast as humans, given 3x faster rate of albumin clearance; we expect this may

translate to similar if not greater weight loss effect in humans although note this is a high dose in NHPs.

~$60B obesity market projected to grow to ~$90B by 2030; tolerability highlighted as a key unmet need. ~2.5B adults and ~390M

adolescents are overweight in the world; by 2035, 25% of the population is estimated to have obesity. Drivers include investment in

improved drugs with convenient ROAs and improved access and affordability, particularly into Medicare. Estimates indicate ~40% of US

adults will have obesity (BMI>30) without T2DM by 2030. Unmet needs include more effective weight loss, preventing weight regain

when stopping medication, weight loss quality (i.e., lean body mass), and tolerability. GI tolerability was highlighted as a key restriction

of current therapies, where n/v/d requires lengthy titration to allow adaptation to GI effects; events commonly emerge during initiation /

dose escalation that can dramatically impact adherence/persistence and discontinuation. In terms of a split from orals to injectables, Dr.

Saunders indicated that injectables will be used for more dramatic weight loss, and if patients do not achieve target weight loss on an

oral they would move to injectables that have been normalized for obesity.

Post-bariatric hypoglycemia (PBH) POC achieved, but Imapextide is deprioritized to focus on obesity portfolio.